The state of California currently has 120 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/26/2025
Locations: Core Healthcare Group, Cerritos, California +3 locations
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Recruiting
This study will test the hypothesis that supplemental synchronous video visits and supplemental asynchronous remote monitoring can each significantly improve glycemic control for pediatric patients with uncontrolled type 1 diabetes over a 6 month period, and will compare health outcomes and patient-centered outcomes between these two intervention arms and a control arm receiving usual care.
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
03/26/2025
Locations: University of California-Davis, Sacramento, California
Conditions: Diabetes Mellitus, Type 1
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Scripps Memorial Hospital, La Jolla, California +2 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Dietary Intervention to Improve Kidney Transplant Outcomes
Recruiting
Randomized controlled trial of a curriculum intervention teaching patients to eat a whole-food plant-based dietary pattern versus standard of care in kidney transplant recipients within the first few months of transplant
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: UC Davis, Sacramento, California
Conditions: Kidney Transplant; Complications, Kidney Diseases, Transplant;Failure,Kidney, Diabetes, Hypertension, Obesity, Diet, Healthy, Lifestyle, Healthy
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Safety follow-up: up to 26 weeks The treatment duration wil... Read More
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
03/25/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400012, San Francisco, California
Conditions: Type 1 Diabetes Mellitus
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Kidney Disease Medical Group, Glendale, California +3 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection
Recruiting
In the United States, only 62% of the 37 million people with diabetes receive annual screening exams for diabetic retinopathy. One of the goals of the US Department of Health and Human Services Healthy People 2030 campaign is to increase diabetic retinopathy screening rates to 70.3%. Research indicates that low screening rates are associated with a variety of factors, including income levels, race and lack of access to care. Furthermore, because diabetic retinopathy frequently presents asymptoma... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/24/2025
Locations: Gastro SB, Chula Vista, California +2 locations
Conditions: Diabetic Retinopathy, Diabetes
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
03/24/2025
Locations: Research Site, Long Beach, California +4 locations
Conditions: Diabetes Mellitus, Type 2
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Recruiting
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Anaheim Clinical Trials, Anaheim, California +3 locations
Conditions: Type 2 Diabetes Mellitus (T2DM)
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: eStudySite, La Mesa, California +1 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Recruiting
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of s... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2025
Locations: Stanford University Medical Center, Stanford, California
Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Safety Evaluation of MiniMed™ 780G System with DS5 CGM in Children
Recruiting
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
Gender:
ALL
Ages:
Between 2 years and 6 years
Trial Updated:
03/20/2025
Locations: Stanford University, Palo Alto, California +1 locations
Conditions: Type 1 Diabetes